Healthy Volunteers (HV) Clinical Trial
Official title:
An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
The primary objective of this protocol is to evaluate [18F]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.
The primary objective of this protocol is to evaluate [18F]MNI-1054 as a Lysine-specific
histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical. The specific objectives
are:
- To measure the dynamic uptake and washout of [18F]MNI-1054 in brain using positron
emission tomography (PET) in healthy volunteers.
- To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform
invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the
brain.
- To acquire safety data following injection of [18F]MNI-1054
- Evaluation of [18F]MNI-1054 PET reliability (test/retest) of the tracer parameters in
healthy volunteers.
;